Avid Bioservices Inc (CDMO)

[freethemice]

Here is an update including gefitinib (Iressa), which was approved for second-line NSCLC based
on equivalence with docetaxel. The trial is one of the 10 in my table for second-line NSCLC.

Shepherd et al , 2000
Docetaxel vs Best Supportive Care (BSC)
DRUG | ORR | PFS | MOS
Docetaxel | 5.5 % | 2.5 mo | 7.5 mo
Placebo | 0 % | 1.5 mo | 4.6 mo

Hanna et al, 2004
Pemetrexed vs Docetaxel
Docetaxel | 8.8 % | 2.9 mo | 7.9 mo
Pemetrexed | 9.1 % | 2.9 mo | 8.3 mo

Shepherd et al, 2005
Tarceva vs BSC
Tarceva | 8.9 % | 2.2 mo | 6.7 mo
Placebo | 1 < % | 1.8 mo | 4.7 mo

Kim et al, 2008
Gefitinib vs. docetaxel
Gefitinib | 9.1 % | 2.2 mo | 7.6 mo
Docetaxel | 7.6 % | 2.7 mo | 8 mo

Ciuleanu et al, 2012
Tarceva vs either docetaxel or pemetrexed (chemo group)
Tarceva | 7.9 % | 1.5 mo | 5.3 mo
chemo | 6.3 % | 2.0 mo | 5.5 mo